INNOVIVA, INC. Proceeds from Sale of Securities, Operating Activities
INNOVIVA, INC. (INVA) reported Proceeds from Sale of Securities, Operating Activities of $8.43 million for the 12-month period ending 2025-12-31, per its 10-Q filed 2026-08-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:ProceedsFromSaleOfSecuritiesOperatingActivities · last filed 2026-08-05
- INNOVIVA, INC. proceeds from sale of securities, operating activities for the quarter ending 2025-12-31 was $3.33M.
- INNOVIVA, INC. proceeds from sale of securities, operating activities for the quarter ending 2025-09-30 was $0.00.
| Period end | Proceeds from Sale of Securities, Operating Activities 3 month | Proceeds from Sale of Securities, Operating Activities 6 month | Proceeds from Sale of Securities, Operating Activities 9 month | Proceeds from Sale of Securities, Operating Activities 12 month |
|---|---|---|---|---|
| 2025-12-31 | $3.33M derived: 10-Q 12 month − 10-Q 9 month · filed 2026-08-05 | $3.33M derived: sum of 2 quarters · filed 2026-08-05 | $8.43M 10-Q · filed 2026-08-05 | |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $5.10M 10-Q · filed 2025-11-05 | ||
| 2025-06-30 | $5.10M 10-Q · filed 2025-08-06 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |